华森制药：接受参与三季度业绩网上说明会的投资者调研

Core Viewpoint - Huason Pharmaceutical (SZ 002907) announced an investor research meeting on November 6, 2025, where the chairman and general manager, You Hongtao, participated in addressing investor inquiries [1] Group 1: Financial Performance - For the first half of 2025, Huason Pharmaceutical's revenue composition was as follows: pharmaceutical manufacturing accounted for 83.53%, pharmaceutical commerce for 15.02%, other businesses for 1.36%, and retail pharmacy for 0.09% [1] - As of the report date, Huason Pharmaceutical's market capitalization was 6.8 billion yuan [1]